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Background: HIV trans-activator protein (Tat) is the crucial factor to control HIV transcription, and is usually considered
as an important immunogen for the design of HIV vaccine. Recent studies reported some special bio-activities of Tat
protein on immunoregulation. However, to date, few studies have focused on exploring the effects of Tat expression
plasmid (pTat) on regulating the immune responses induced by HIV DNA vaccines. In this study, our main objective is
to investigate the immunoregulation mediated by pTat in mice.
Methods: Four gene-coding plasmids (pTat, pGag, pEnv and pPol) were constructed, and the gene expression was
detected by western blot method. The effects of pTat on regulating the immune responses to antigens Gag, Env, Pol
were assessed by enzyme-linked immunospot and enzyme-linked immunosorbent assay. The data was analysed by
one-way analysis of variance.
Results: After two immunizations, mice vaccinated with antigen expressing plasmid (pGag, pEnv or pPol) plus pTat
exhibited significantly stronger IFN-gamma response than that vaccinated with the corresponding antigen alone.
Moreover, mice receiving two injections of antigen plus pTat exhibited the same strong IFN-gamma response as those
receiving three injections of antigen alone did. Furthermore, addition of pTat not only induced a more balanced Th1
and Th2 response, but also broadened IgG subclass responses to antigens Gag and Pol.
Conclusion: pTat exhibited the appreciable effects on modulating immune responses to HIV antigens Gag, Env and
Pol, providing us interesting clues on how to optimize HIV DNA vaccine.
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For a long time, traditional vaccines played the vital roles
in controlling and eradicating infectious diseases that are
life threatening, such as smallpox, cholera and polio [1].
In the early 1990s, Wolff and his colleagues directly
injected mice with naked DNA plasmid, and found in sur-
prise that antigen-specific T cell response could be in-
duced by this simple way [2]. Further, they reported that
the gene expression lasted for one year after intramuscular
injection of the DNA plasmid [3]. From that time on, re-
searchers redefined the nature of vaccine and realized that* Correspondence: yulongc@263.net; yshao08@gmail.com
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reproduction in any medium, provided the orthe genetic material coding antigen sequence could be
used as the effective vaccine component.
DNA vaccines against human immunodeficiency virus
(HIV) have been developed for nearly 20 years [4]. The
characteristics of HIV DNA vaccines were also evaluated
in many studies, indicating the good properties on safety,
stability and easy-production [4-6]. Currently, one of the
major challenges for HIV DNA vaccine development is its
relatively modest immunogenicity in some animal models
and in clinic trials [7]. To solve this problem, researchers
tried a variety of methods, including developing cytokine
genetic adjuvant such as IL-2, GM-CSF and IL-12, im-
proving DNA delivery by gene gun or electrostimulation,
modifying the properties of antigen presenting cells, and
optimizing the antigen coding sequence to achieve higher
gene expression level [8-14].
HIV Tat is the important transcription activation pro-
tein. It contains several distinct regions on the basis ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gion, cysteine-rich role domain, core region, basic region
and glutamine-rich region. Tat protein is encoded by
two exons. The first exon is conserved in all viral isolates
and encodes a 72-amino acid peptide which mediates
the virus trans-activation [15]. The C-terminal amino
acids which are encoded by the second Tat exon contain
the arginine-glycine-aspartic acid (RGD) motif and me-
diate cell adhesion and binding of extracellular Tat [16].
In most cases, HIV-1 Tat is used as an immunogen
[17,18]. However, the published data had also exhibited
some other biological functions of Tat protein, such as
inducing maturation of monocyte-derived dendritic
cells (MDDCs), triggering a Th1-type dominant adap-
tive immune response, changing the subunit com-
position of the proteasome, modulating the humoral
responses against unrelated antigens [19-22], and so on.
Therefore, it may be hypothesized that Tat expression
plasmid as a regulator modulates the immune responses
against other crucial HIV antigens to optimize the efficacy
of HIV vaccines.
In our current study, we constructed the Tat-expression
plasmid (pTat) and added it directly into other HIV DNA
vaccine component. By investigating the immune responses
to HIV-1 antigens (Gag, Env and Pol), we found that pTat
greatly improved T cell responses to these HIV antigens in
mice, and such enhancement of antigen-specific T cell re-
sponse by pTat was not caused by simply increasing the ex-
pression of target antigen . We also demonstrated that pTat
could regulate Th skewed responses and broaden IgGFigure 1 Antigens-specific T cell responses. In test groups, female BalB/
absence or presence of pTat. Blank plasmid group was used as negative co
reactive epitopes between Tat and HIV antigens Gag, Env and Pol (splenoc
Env and Pol peptides, respectively). Fresh splenocytes were stimulated by t
response was detected by ELISPOT assay. These experiments were repeate
specific IFN-gamma response (splenocytes were stimulated by Gag peptide
(50 μg pGag and 50 μg empty vector each time); “pGag + pTat(2)”: two imm
expression plasmid (50 μg pGag and 50 μg pTat each time); “pGag(3)”: thre
50 μg empty vector each time); “pTat”: two immunizations with pTat (50 μ
with empty vector (100 μg each time). Part B (Env-specific IFN-gamma resp
the same manner. Symbol** means P < 0.01; Symbol* means P < 0.05.subclass responses to antigens Gag and Pol. Collectively,
our results suggested that pTat could effectively shape the
immune responses triggered by HIV DNA vaccines.
Results
Effects of pTat on cellular immune responses to HIV
antigens Gag, Env and Pol
In this study, we first investigated whether pTat could ef-
fectively enhance T cell responses to three HIV antigens
(Gag, Env and Pol) in mice. The production of IFN-
gamma by splenocytes from immunized mice was detected
by enzyme-linked immunosorbent spot (ELISPOT) ana-
lysis. As shown in Figure 1A , after two intradermal vacci-
nations, pGag plus pTat (mixture of 50 μg pGag and 50 μg
pTat) induced nearly six times stronger Gag-specific IFN-
gamma response than that pGag alone did (mixture of
50 μg pGag and 50 μg blank plasmid). Using the same
immunization protocol, significantly enhanced IFN-gam-
ma responses to Env and Pol were also detected in mice
vaccinated with pEnv + pTat and pPol + pTat respectively,
compared with the mice vaccinated with pEnv and pPol
alone (showed in Figure 1B and Figure 1C).
Subsequently, enhanced cellular immune responses to
three HIV antigens by pTat were confirmed again in our “re-
ducing immunization times” experiment. In the case of Env
and Pol, mice receiving two vaccinations with pEnv plus
pTat or pPol plus pTat produced the same high amount of
IFN-gamma as those receiving three injections of pEnv or
pPol alone, respectively (Figure 1B and Figure 1C). More
encouragingly, two vaccinations with pGag plus pTatC mice were intradermally vaccinated with pGag, pEnv or pPol, in the
ntrol. pTat alone group was designed to test whether there are cross-
ytes from mice vaccinated with pTat alone were stimulated by Gag,
he corresponding positive peptides, and antigen-specifc IFN-gamma
d once. The data was shown as means ± SD. Part A showed the Gag-
). “pGag(2)”: two immunizations with Gag expression plasmid alone
unizations with the mixture of Gag expression plasmid and Tat
e immunizations with Gag expression plasmid alone (50 μg pGag and
g pTat and 50 μg empty vector each time); “blank”: two immunizations
onse) and Part C (Pol-specific IFN-gamma response) can be done in
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three vaccinations with pGag alone did (p < 0.05, Figure 1A).
These results suggested that addition of pTat could induce
satisfied antigen-specific T cell response in the case of re-
ducing immunization times. In other word, addition of
pTat could shorten the immunization cycle effectively.
We also detected the production of IL-4 that was consid-
ered as one Th2-type cytokine for promoting B-cell matur-
ation in all above-mentioned mice groups [23-25]. In
contrast to the IFN-gamma responses, the ELISPOT results
showed that neither pGag, pEnv and pPol stimulated the
antigen-specific IL-4 production, nor the addition of pTat
enhanced the secretion of IL-4 to a detectable level, (nega-
tive, data not shown).
PTat failed to enhance HIV antigen expression in vitro
To understand the reasons leading to the increased antigen-
specific IFN-gamma response mediated by pTat, we first in-
vestigated the effects of pTat on enhancing the expressions
of HIV antigens Gag, Env and Pol. Serially diluted antigen
expression plasmids, pGag, pEnv or pPol (1 μg, 2 μg and
4 μg for each plasmid), were transfected into 293 T cells in
the absence or presence of pTat. Different amount of plas-
mid DNA was used in our transfection experiment to avoid
the potential saturation effect. By comparing the values of
relative integral optical density of target proteins, we found
that, at the same dose of antigen expression plasmid, the ex-
pression of target antigen (Gag, Env or Pol) in 293 T cells
which were transfected with antigen coding plasmid plus
pTat was similar with that in cells receiving the correspond-
ing plasmid alone. The results suggested that the expression
of none of three HIV antigens (Gag, Env and Pol) was af-
fected by the addition of pTat (Figure 2).
To explore whether no-expression of Tat protein
(encoded by pTat) led to no-regulation of pTat on the
expressions of three antigens (Gag, Env and Pol), we also
detected Tat expression in 293 T cells which were
transfected with pTat alone (4 μg pTat and 4 μg empty
vector), pTat + pGag (4 μg pTat and 4 μg pGag), pTat +
pEnv (4 μg pTat and 4 μg pEnv) and pTat + pPol (4 μg
pTat and 4 μg pPol), respectively. The results indicated
that the same strong Tat expression levels (detectable)
were detected in these cell-transfection groups (as
shown in Figure 3A and Figure 3B).
Together, our results demonstrated that pTat had no
effects on increasing the in vitro expression of antigens
Gag, Env and Pol, suggesting that enhanced IFN-gamma
responses against target antigens were not due to that
these antigens achieved the higher protein expression.
No cross-reactive T cell epitopes between Tat and Gag,
Env, Pol
In order to exclude the possibility that there are cross-
reactive epitopes within Tat which were shared withGag, Env or Pol, we prepared splenocytes from mice re-
ceiving two intradermal vaccinations with pTat alone
(50 μg pTat each time), and stimulated them with Gag,
Env or Pol peptides, respectively. The results showed that
negative Tat-specific IFN-gamma responses were detected
from splenocytes challenged with Gag, Env or Pol peptides
(Figure 1A, Figure 1B and Figure 1C), suggesting that the
cross-reaction between Tat and target antigens (Gag, Env
or Pol) was not the reason for enhanced IFN-gamma re-
sponse to HIV antigens by pTat.
Effects of pTat on the total IgG responses to HIV antigens
Gag, Env and Pol
We then evaluated the effects of pTat on the total IgG re-
sponses to HIV antigens Gag, Env and Pol by measuring
IgG titers in serum samples from vaccinated mice (the
same mice as those described in Figure 1 by enzyme-linked
immunosorbent (ELISA) assay. As showed in Figure 4A,
the results showed that pPol alone induced the same
strong IgG response as vaccination with pPol plus pTat did
in mice. Similarly, compared with pGag-vaccination alone,
pGag plus pTat only induced the limited enhancement of
Gag-specific IgG titer, which was not statistically significant
(p > 0.05). The same result was also exhibited in the case of
pEnv. Collectively, these results suggested that pTat had
limited effect on boosting the total IgG responses to HIV
antigens Gag, Env and Pol.
Effects of pTat on IgG subclass production
We further investigated the effects of pTat on IgG sub-
class production by measuring the titers of three IgG sub-
classes (IgG1, IgG2a and IgG3) in mice serum samples. As
shown in Figure 4B, after two intradermal immunizations,
both pEnv alone and pEnv plus pTat induced positive
IgG1, IgG2a and IgG3 responses to Env. In the case of
Gag and Pol, positive IgG1 and IgG3 responses to Gag
and Pol were detected in all mice groups receiving pGag
and pPol respectively, regardless of the presence or ab-
sence of pTat. In contrast, positive IgG2a responses to
Gag and Pol were detected only in mice immunized with
pGag plus pTat and pPol plus pTat, but not in mice im-
munized with pGag and pPol alone. These results sug-
gested that pTat broadened the IgG subtype responses to
Gag and Pol.
Effects of pTat on Th polarization
We then compared the IgG1 (Th2 polarization) and IgG2a
(Th1 polarization) subclass responses generated by three
antigen expressing plasmids (pGag, pEnv and pPol) immu-
nizations with or without pTat, respectively. By calculating
Th1:Th2 index according to the formula of “IgG2a/IgG1”,
we found that the Th1:Th2 index in mice vaccinated with
pGag, pEnv and pPol alone were 0.17, 1.08 and 0.25, re-
spectively (Table 1), indicating that pGag and pPol alone
Figure 2 In vitro expressions of antigen Gag, Env and Pol. 293T cells were prepared at a density of 1×106 cells per well and 90% cell viability
the night before transfection. Each plasmid (pGag, pEnv or pPol) was delivered to cells at three dose level (1 μg, 2 μg and 4 μg) respectively.
Forty-eight hours after transfection, the expressions of antigens were detected by WB method, and the relative integral optical densities of
antigens were measured (the average of two experiments with SD was indicated). Empty vector was used as blank control and β-actin was
selected as internal control. Part A: the expressions of Gag were showed (left side): Gag-expression plasmids were delivered to 293T cells at three
dose levels (1 μg, 2 μg and 4 μg) respectively, in the presence of pTat or in the absence of pTat. The expressions of Gag were quantified by
detecting the relative integral optical densities of Gag antigen (right side): “pGag (1 μg)+pTat”, “pGag (2 μg)+pTat” and “pGag (4 μg)+pTat” means
that pGag were delivered to cells at the dose of 1 μg, 2 μg and 4 μg respectively, in the presence of pTat. “pGag (1 μg)”, “pGag (2 μg)” and
“pGag (4 μg)” means that pGag alone were delivered to cells at the dose of 1 μg, 2 μg and 4 μg, respectively. “Blank” means empty vector was
delivered to cells. Part B (the expressions of Env) and C (the expressions of Pol) can be done in the same manner.
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pEnv alone induced a balanced Th1/Th2 response. Never-
theless, addition of pTat turned the Th2 dominant antibody
responses to Gag and Pol into the more balanced Th1/Th2
responses (Th1:Th2 index for Gag and Pol was 1.17 and 2,
respectively). Therefore, the results suggested that pTat
had effects on shaping Th polarization induced by HIV
DNA vaccines pGag and pPol.
Tat-specific immune responses in mice
Tat-specific immune responses were also detected in our
current study. After two immunizations, mice vaccinated re-
spectively with pTat alone, pTat plus pGag, pTat plus pEnv,pTat plus pPol and empty vectors were sacrificed, and the
splenocytes and serums were harvested for ELISPOT and
ELISA assay. As shown in Figure 3C, all four mice groups
(pTat alone, pTat plus pGag, pTat plus pEnv, pTat plus pPol)
exhibited the positive Tat-specific T cell response, but no sig-
nificant differences among these test groups (P > 0.05). In
the case of antibody response against Tat, similarly strong
antibody responses (positive) were also detected in all four
pTat-immunization mice groups (Figure 3D). The results
indicated that pTat could induce the positive T cell and
antibody responses to Tat itself. Moreover, it also might
suggest that pGag, pEnv and pPol had no influences to the
immune response against HIV Tat.
Figure 3 In vitro expression and immune response of Tat. Part A and B showed the Tat expression in 293 T cells. Briefly, 293 T cells (1 × 106
cells per well, and 90% cell viability at least) were transfected with pTat alone, pGag + pTat, pEnv + pTat, pPol + pTat and empty vectors,
respectively. Forty-eight hours after transfection, Tat expressions in above-mentioned cell groups were detected by WB method (Figure 3A), and
the relative integral optical density of Tat protein in each group was measured (Figure 3B). Empty vector transfection was used as blank control
and β-actin was selected as internal control. In part A and B: pTat alone, pGag + pTat, pEnv + pTat, pPol + pTat means that 293 T cells received
4 μg pTat plus 4 μg empty vector, 4 μg pTat plus 4 μg pGag, 4 μg pTat plus 4 μg pEnv, 4 μg pTat plus 4 μg pPol, respectively. Blank: cells were
transfected with 8 μg empty vector. Part C and D showed the Tat-specific immune responses. Female BalB/C mice were immunized twice. Two
weeks after the final vaccination, mice were sacrificed and the spleens and blood were harvested. Tat-specific T cell and antibody responses were
detected with IFN-gamma ELISPOT and IgG ELISA assay, respectively. In part C and D, pTat alone: mice received 50 μg pTat and 50 μg empty
vector each time; pGag + pTat/ pEnv + pTat/ pPol + pTat: mice received 50 μg pGag/ pEnv/ pPol and 50 μg pTat each time; Blank: mice received
100 μg empty vector each time.
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As an important regulator in the early stage of HIV in-
fections, Tat protein mainly exerts its biological function
on controlling HIV transcription when the proviral gen-
ome is transported to the nucleus and integrated into
the host cell genome [29]. However, in the recent ten
years, accumulating studies have showed some other
natural bioactivities of Tat protein on shaping immune
characters of other antigens, providing us clues for de-
signing new vaccines against AIDS.
In fact, Tat protein as a vaccine component had been
used in clinic trial, and exhibited some special effects on
optimizing vaccine efficacy. Ensoli et al. in their Phase II
clinical investigation demonstrated that therapeutic im-
munization with Tat induced a safe and durable immune
response, modified the pattern of CD4+ and CD8+ cellular
activation, increased the T cell response against Env, as well
as effectively intensified HAART efficacy and restored im-
mune homeostasis, providing the encouragement for com-
bining Tat immunization with conventional virus-targeting
drugs for an improved treatment of HIV disease [30]. Inanimal models, Tat protein as immunogen or regulator had
been assessed more completely. For example, Florese J et al.
reported for the first time that Tat protein served as a target
for ADCC and Tat specific antibody mediated ADCC kill-
ing in macaques [31]. And Tat protein was also found to
possess auto-adjuvanticity to raise an adjuvant-free humoral
immune response against Tat itself controlled by its core
region in mice [32]. Other researchers explored the effects
of Tat on favoring protective immunity against Leishmania
major in mouse model [33]. Moreover, the HIV vaccines
based on Tat were also demonstrated to be immunogenic
and be able to protect macaques from mucosal or intraven-
ously simian/human immunodeficiency virus (SHIV) chal-
lenge [34,35].
To date, most investigations against the regulation of
HIV Tat on immune responses induced by vaccines were
based on Tat protein, and few studies reported the regu-
lation activities of Tat DNA, especially Tat expression
plasmid. Actually, Tat expression plasmid (pTat) itself
possesses some special advantages, compared with Tat
protein or virus vector encoding Tat: (1) pTat could be
Figure 4 Antigens-specific antibody responses. Serum samples from mice vaccinated twice were harvested two weeks after the second
immunization (The same mice as described in Figure 1). The titers of total IgG and three IgG subclasses (IgG1, IgG2a, IgG3) in each mouse serum
were evaluated by standard ELISA assay (repeat once, 1:50 start dilution). The results are mean value (Log10 value) of each group of mice (n = 6) ± SD.
Part A and Part B showed the total IgG and IgG subclasses responses to Gag, Env and Pol, respectively. pGag/ pEnv/ pPol: two immunizations, 50 μg
pGag/ pEnv/ pPol and 50 μg empty vector each time; pGag + pTat/ pEnv + pTat/ pPol + pTat: two immunizations, 50 μg pGag/ pEnv/ pPol and 50 μg
pTat each time.
Table 1 Th polarization
pGag (titer) pGag + pTat (titer) Blank (titer)
IgG1 (Th2) 300 300 50 (negative)
IgG2a (Th1) 50 (negative) 350 50 (negative)
Th1:Th2 index 0.17 1.17 –
pEnv (titer) pEnv + pTat (titer) Blank (titer)
IgG1 (Th2) 600 750 50 (negative)
IgG2a (Th1) 650 750 50 (negative)
Th1:Th2 index 1.08 1 –
pPol (titer) pPol + pTat (titer) Blank (titer)
IgG1 (Th2) 200 200 50 (negative)
IgG2a (Th1) 50 (negative) 400 50 (negative)
Th1:Th2 index 0.25 2 –
The mean value of each group of mice (the same data as showed in Figure 4B)
was showed in this table, and used to calculate the index of IgG2a/IgG1 [26]. Th-
polarization response in mice was determined according to the value of IgG2a/
IgG1 [27,28]. The value of Th1:Th2 are accurate to two decimal places. All
experiments were repeated once, and the results were consistent.
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sider to elicit the anti-vector immune responses in the
process of vaccination; (2) commercialized production of
pTat is relatively inexpensive; (3) pTat itself is stable and
convenient for transportation. Therefore, Tat-expression
plasmid as a vaccine component should be an appropriate
candidate. In our current study, we demonstrated that pTat
which encodes the full length Tat gene (contains two exons,
101 amino acids) could enhance IFN-gamma responses
against three vital antigens (Gag, Env and Pol) used in HIV
vaccines. Moreover, the enhancement of Gag-specific T cell
response caused by addition of pTat was proved to be bet-
ter than that caused by linking ubiquitin to Gag (data not
shown), which was considered as an effective strategy for
improving antigen-specific cellular immune response in
many foregoing studies [36,37], suggesting the excellent
capability of pTat on enhancing IFN-gamma production.
Similar enhancement of Gag-specific T cell response by Tat
was also reported in Zhao et al. paper which showed that
co-delivering of Tat and Gag with the Ad5hr vector en-
hanced Gag-specific IFN-gamma response [38]. Moreover,
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adjuvant had the property of broadening and enhancing T
cell responses to HIV structural antigens (Env and Gag)
and unrelated antigen (ovalbumin) in mice [39], via modi-
fying the composition of the proteasome and its enzymatic
activities [21,40]. Such enhancement of IFN-gamma re-
sponse to crucial antigens (such as Gag, Env and Pol) is
considered to be meaningful for optimizing the efficacy of
HIV vaccine. Our previous research showed that HIV-
specific T cell IFN-gamma response is associated with
seronegative status in highly exposed subjects in China,
suggesting that a strong IFN-gamma immunity against
HIV may be helpful to prevent the infection or control the
progression of HIV [41]. To understand the reasons of the
enhancement of T cell responses to other HIV antigens
caused by pTat, we first investigated whether pTat would
up-regulate these antigen expressions. The WB results
showed that pTat failed to promote the expressions of
other HIV antigens in vitro. Moreover, we also excluded
the possibility that cross-reactive epitopes within Tat
which were shared with Gag, Env and Pol resulted in the
enhancement of T cell responses against Gag, Env and
Pol. Of note, some previous studies provided us more
clues to explore the mechanism how Tat enhanced T cell
responses against other antigens. Barbara Ensoli group
demonstrated that the enhanced capability of DCs in cap-
turing antigens caused by Tat was the major factor leading
to the enhanced antigen-specific T cell responses. Specific-
ally, Tat was able to stimulate the maturation of CD1a-
expressing MDDCs, improve the capability DCs in captur-
ing antigens, up-regulate MHC and costimulatory mole-
cules, as well as induce high cytokine production [20]. In
addition, the study from Guoqing Zang group showed that
the protein transduction domains (PTD) of HIV Tat pro-
tein could interact with exogenous antigens and help them
enter cells, resulting in increased cytokine production [42].
In contrast, Shalini Gupta et al. found that Tat suppressed
the cellular immune response to HIV Env/gp120 in mice
when gp120 and Tat were delivered by the bicistronic ex-
pression vector, since Tat induced strong secretion of
IL-10 which has appreciable T cell inhibitory activity
[43]. Similar inhibition was also found in the study by
Mooij et al., showing that immunization with com-
bined antigens (Tat-Gag-Env) reduced the magnitude
of the response to Tat compared to the single-antigen
immunization [44].
Regarding the effects of pTat on modulating humoral
immune responses, our results showed that pTat had no
effects on increasing the total IgG titer against Gag, Env
and Pol in mice. It was inconsistent with the result from
another group: they found that the auto-adjuvanticity of
Tat protein could be transferred to unrelated antigens
and enhanced these antigens specific humoral immune
responses [22]. Meanwhile, the humoral responsecharacterized by the broad anti-HIV IgG subclasses was
demonstrated to be associated with the long-term no
progress (LTNP) status in some previous clinical reports
[30,45,46]. Therefore, we further investigated the IgG
subclass responses in mouse serum samples. The results
showed that, compared with the mice vaccinated with
pGag or pPol alone, the broader IgG subclass responses
to Gag and Pol were induced upon the addition of pTat.
Moreover, our result also indicated that pTat could turn
the Th2-polarization responses induced by pGag and
pPol alone to the more balanced Th1/Th2 immune re-
sponses in mice. Similar results were reported in the
study by Kulkarni et al., which showed Tat modulated
Th1 differentiation as well as the class switch recombin-
ation to IgG2a of B cells via up-regulating the transcrip-
tion factor T-bet [47].
Besides, biosafety is another major concern needed
to be considered during the DNA vaccine design. Our
plasmid backbone was optimized to minimize the po-
tential adverse effects by deleting unnecessary prokary-
otic elements or replacing those functional regions
derived from prokaryotic genes [48]. Moreover, the an-
tigens used in our current study have also been modi-
fied by deleting or mutating the toxic sites within the
antigen-coding genes. More importantly, the DNA vac-
cines used in our current research have already entered
Phase I clinic trials after receiving satisfied safety as-
sessment from the good laboratory practice toxicology
study in animal models (data not shown).
Finally, it should be noted that the enhancement of
T cell response by Tat in this study was tested in BalB/
C mice. Some published data showed that the pattern
of Th1/Th2 response induced by Tat protein was dif-
ferent between mice and cynomolgus macaques [49].
Therefore, whether a similar effect can be observed in
nonhuman primates and humans needs to be determined
in further experiments. Considering the significant en-
hancement of T cell responses and the broadened range of
IgG subclass production achieved by pTat, our study pro-
vided a new strategy to optimize the efficacy of HIV DNA
vaccine.
Conclusion
In this study, HIV Tat expression plasmid significantly
enhanced IFN-gamma responses to crucial antigens
(Gag, Env, Pol) used in HIV vaccines in mice. Moreover,
it also has been found to broaden IgG subclass responses
to Gag and Pol, and induce a more balanced Th1 and
Th2 response.
This study demonstrated the effects of Tat expression
plasmid on modulating immune responses to other HIV
antigens, and provided the evidence that Tat expression
plasmid as a regulator could be used to enhance the effi-
cacy of HIV DNA vaccine. The present study raises the
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developed into a novel vaccine component to optimize
HIV vaccines in clinical trials.
Methods
Ethics statement
Animal experiments were approved by the Animal Ethics
Committee of Chinese P. L. A. General Hospital, and were
carried out in accordance with the guidelines of the Beijing
Municipality on the Review of Welfare and Ethics of La-
boratory Animals. Mice were anesthetized with Zoletil 50
(Virbac, SanteAnimale) in phosphate-buffered saline (PBS)
by subcutaneous administration immediately prior to vac-
cination or sacrifice.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
Plasmids construction
Expression plasmid pDRVI1.0 is an optimized mamma-
lian expression vector constructed by Prof Yiming Shao
group. It contains intronA sequence of CMV promoter
and BGH polyA signal [50,51]. Genes coding Gag, Env,
Pol or Tat were obtained from HIV-1 CN54 (a CRF07_BC
strain) and cloned into pDRVI1.0 separately by standard
method. All four constructs (pGag, pEnv, pPol and pTat
showed in Figure 5) were verified by restriction enzyme
analysis and sequencing, and purified by Qiagen (Va-lencia
CA) endotoxin-free columns.
Western blot (WB) analysis
293 T Cells (ATCC, CRL-11268) cultured with DMEM
containing 10% fetal bovine serum were seeded in six-
well plate at a density of 1 × 106 cells/well and at least
90% cell viability. The cells were transfected with one
kind of antigen-expression plasmid (pGag, pEnv or pPol)
in the absence or presence of pTat using lipofectamine-Figure 5 Schematic maps of HIV genes expression plasmids. pGag, pE
protein, respectively. CMV, human cytomegalovirus (hCMV) immediate/earl
hormone polyadenylation signal.2000 (Invitrogen, Carlsbad, CA) at a ratio of 1.5 μl
lipofectamine-2000 to 1 μg plasmid DNA. Each antigen-
expression plasmid was delivered to 293 T cells at
three dose levels (1 μg, 2 μg and 4 μg) respectively. Ap-
propriate dose of blank plasmid was added into the
transfection wells to ensure that the cells per well received
the same amount of plasmid. The cells were harvested
48 hours after transfection and lysed with lysis buffer
(20 mM Tris–HCl, pH7.5, 150 mM NaCl, 1 mM EDTA-
Na2, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophos-
phate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 μg/ml
leupeptin). PIC and 1 mM PMSF were added into lysis
buffer to prevent protein degradation. Cell lysates were
centrifuged at 14,000 × g for 10 minutes, and the proteins
in supernatants were boiled for 5 minutes, separated by
12% SDS-PAGE and transferred onto PVDF membranes.
The membranes were blocked with 5% skimmed milk in
Tris-buffered saline with 0.05% Tween20 (TBST) for one
hour at room temperature and incubated with primary
antibodies (Positive IgG response serums from mice vacci-
nated with pTat, pGag, pEnv or pPol respectively; Rabbit
anti-β-actin polyclone antibody purchased from Santa
Cruz Biotechnology, Santa Cruz, CA) at 1:500 dilution at
4°C overnight. The membranes were then washed with
TBST, incubated with secondary goat-anti-rabbit antibody
or goat-anti-mouse antibody coupled to horseradish per-
oxidase (HRP) (Santa Cruz Biotechnology, Santa Cruz,
CA) at 1:2000 dilution for one hour at room temperature,
and developed with chemiluminescent detection reagent.
Finally, WB membranes were scanned and quantified
using the Gel/Chem doc program Quantity one (Bio-Rad,
Milan, Italy). Protein expression levels were obtained from
images using the Quantity One software (v.4.5.1; Bio-Rad).Mice immunization
Female BalB/C mice of six to eight weeks old were
obtained from the Laboratory Animal Center in the
Academy of Military Medical Sciences in China. The mice
were randomly divided into eleven groups with six micenv, pPol and pTat means the plasmid encoding Gag, Env, Pol and Tat
y (IE) promoter; Intron, hCMV IE intronA; BGH pA, bovine growth
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injections), pGag plus pTat (two injections), pEnv alone
(two injections), pEnv alone (three injections), pEnv plus
pTat (two injections), pPol alone (two injections), pPol
alone (three injections), pPol plus pTat (two injections),
pTat alone (two injections) and blank (two injections).
Purified plasmids were reconstituted in endo-free H2O
for intradermal immunization. The dose of each plas-
mid DNA was 50 μg per mice each time. 50 μg empty
vector was used in mice which were vaccinated with
only one plasmid DNA to ensure all mice received a
total of 100 μg plasmid. The spacing interval between
two vaccinations was three weeks. Two weeks after the
final vaccination, mice were sacrificed and the spleens
and blood were harvested. Fresh splenocytes were pre-
pared for ELISOPT assay and serum samples were pre-
pared for ELISA assay.
Enzyme-linked immunosorbent spot (ELISPOT) assay
ELISPOT assay was finished using commercial kits from
BD Pharmingen (mouse IFN-gamma and IL-4 ELISPOT
sets). Briefly, cytokine capture antibody against mouse
IFN-gamma or IL-4 (1 μl/200 μl sterile PBS) was coated
onto PVDF in 96-well plates by overnight incubation at
4°C. The plates were blocked with complete 1640
containing 10% FBS for two hours at room temperature.
Fresh prepared mice splenocytes (5 × 105 cells/well)
were added into the plates immediately after the
addition of 5 μg/ml specific H-2d-restricted CD8+ pep-
tides (peptide sequences: Gag, AAMQILKDTINEEAA;
Env pool, DTEVRNVWATHACVPADPNP, SELYK-
YKVVEIKPLGVAPTT, QQSNLLRAIEAQQHLLQLTV;
Pol pool, GTVLVGPTPV- NIIGR, VGPTPVNIIGRN-
LLT, HGVYYDPSKDLIAE, YYDPSKDLIAEIQKQ; Tat,
IFYGRKERRQERSAH). The plates were incubated for
24 hours at 37°C with 5% CO2, and washed four times
with PBST (0.05% Tween20). Then, the plates were in-
cubated with 2 μg/ml biotinylated detection antibody
against mouse IFN-gamma or IL-4 for two hours.
ELISPOT development was performed by one hour in-
cubation with avidin-HRP complex in PBST, followed
by washing four times with PBS. Finally, the plates were
incubated with peroxidase substrate AEC for 30 minutes.
ELISPOT spots were measured with the automated
ELISPOT Reader System (Bio-Red). For each mice group,
the cut-off value to consider a positive response by
ELISPOT was that: (1) the number of specific spots per
well had to be at least two times the average value found in
negative control wells; (2) the average value in negative
control wells had to be not more than 20 spot forming
units/SFU per million splenocytes; (3) the response had to
be higher than 50 SFU per million splenocytes [52,53].
Splenocytes from mice vaccinated with empty vectors were
used as negative/blank controls.Enzyme-linked immunosorbent (ELISA) assay
ELISA assay was performed to measure antibody titers in
mouse serum samples. 96-wells flat bottom plates (Costar,
Corning, NY) were coated with one of the three purified re-
combinant proteins (Gag/P24 protein, Env/gp120 protein,
Pol/P51 protein; These proteins were home-made in E.coil
expression system, and derived from a major epidemic strain
in China, CN54, which is derived from the Chinese isolate
97CN001 which is a B/C recombinant strain. The purity of
target proteins is >90%) at a concentration of 0.01 μg/ml in
coating buffer (0.012 mol/L Na2CO3, 0.038 mol/L NaHCO3,
pH9.6) at 4°C overnight. The plates were washed five times
with PBST, and blocked with 3% BSA in PBST at 37°C for
one hour. Mouse serum samples were diluted with blocking
solution, and added into each well (100 μl/well). After incu-
bation at 37°C for one hour, the plates were washed five
times with PBST and then incubated with 1:5000 diluted
HRP-labeled antibodies against mouse IgG, IgG1, IgG2a or
IgG3 (Santa Cruz Biotechnology) at 37°C for one hour. The
plates were then washed five times with PBST. After the
final wash, 100 μl fresh-prepared TMB substrate solution
(Sigma, St. Louis, MO) was added into each well, and the
plates were incubated for 5 minutes. The reaction was
stopped by addition of 25 μl 2 M H2SO4. The optical density
(OD) was measured at 450 nm by Multiscan enzyme-linked
immunosorbent assay plate reader (Thermo Life Sciences,
Hampshire, United Kingdom). The cut-off value was deter-
mined: (1) a OD450nm value >0.1 at the dilution of 1:100
(if not, the sample was considered as negative) and (2) at
least three folds that of the negative control were considered
as positive [54,55]. Endpoint titers were expressed as Log10
concentrations. The serum samples from empty vector vac-
cination mice were considered as negative control.Th1:Th2 index calculation
Th1:Th2 index was calculated as previously described
[27,28]. Specifically, antibody titers above 100 were con-
sidered positive whereas antibody titers under 100 were
considered negative and excluded from the data analysis.
In each group, the average value of antibody titer at the
last positive dilution for each IgG subclass was used.
Th1:Th2 index was calculated according to the formula
of IgG2a/IgG1.Statistical analysis
Values were expressed as means ± standard deviations
(SD). Analysis of differences in means between groups
was conducted by one-way analysis of variance (ANOVA);
P < 0.05 was considered significant.Competing interests
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